IART

MKT CAP:$814M

Integra LifeSciences Holdings Corporation

Market Cap

$814M

Healthcare·Medical - Devices·🇺🇸 United States·NASDAQ

Healthcare·Medical - Devices·🇺🇸·NASDAQ

Stock Price

$10.75-$1.26 (-10.49%)

Apr 22, 2026

Company Details

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Su...

CEO

Mojdeh Poul

IPO Date

Aug 16, 1995

Website

www.integralife.com

Key Metrics TTM

Revenue

$1.6B

+5.0% YoY

Net Income

-$495M

EPS (Diluted)

-$6.48

Free Cash Flow

-$14M

Revenue / Share

$21.41

Gross Margin

53.5%

Operating Margin

-27.5%

Net Margin

-30.1%

FCF Margin

-0.9%

P/S

0.5x

P/E

—

Earnings Reports

Q4 2025

May 4, 2026

PENDING

FY 2025

Feb 26, 2026

$1.6B+1.5%EPS -$6.73

Q3 2025

Oct 30, 2025

$402M+5.6%EPS -$0.07

Q2 2025

Jul 31, 2025

$416M-0.6%EPS -$6.33

Q1 2025

May 5, 2025

$383M+3.7%EPS -$0.33

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 21	$406M	$249M	$58M
Q1 22	$377M	$234M	$46M
Q2 22	$398M	$249M	$60M
Q3 22	$385M	$237M	$65M
Q4 22	$398M	$250M	$68M
Q1 23	$381M	$233M	$36M
Q2 23	$381M	$207M	$13M
Q3 23	$382M	$218M	$27M
Q4 23	$397M	$226M	$36M
Q1 24	$369M	$207M	$4M
Q2 24	$418M	$226M	-$3M
Q3 24	$381M	$200M	-$8M
Q4 24	$443M	$249M	$36M
Q1 25	$383M	$194M	-$15M
Q2 25	$416M	$209M	-$513M
Q3 25	$402M	$226M	$40M

Valuation

Quarter	P/S	P/E
Q4 21	0.5x	4.8x
Q1 22	0.5x	5.2x
Q2 22	0.5x	4.9x
Q3 22	0.5x	4.7x
Q4 22	0.5x	4.5x
Q1 23	0.5x	4.7x
Q2 23	0.5x	6.2x
Q3 23	0.5x	8.1x
Q4 23	0.5x	12.0x
Q1 24	0.5x	20.2x
Q2 24	0.5x	34.4x
Q3 24	0.5x	—
Q4 24	0.5x	—
Q1 25	0.5x	—
Q2 25	0.5x	—
Q3 25	0.5x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 21	$69M	$42M
Q1 22	$44M	$30M
Q2 22	$66M	$57M
Q3 22	$68M	$59M
Q4 22	$85M	$71M
Q1 23	$26M	$12M
Q2 23	$28M	$13M
Q3 23	$27M	$14M
Q4 23	$59M	$34M
Q1 24	$16M	$291.0K
Q2 24	$40M	$11M
Q3 24	$22M	-$7M
Q4 24	$51M	$11M
Q1 25	-$11M	-$40M
Q2 25	$9M	-$11M
Q3 25	$41M	$26M

Capital Expenditures

Quarter	CapEx
Q4 21	$27M
Q1 22	$14M
Q2 22	$9M
Q3 22	$9M
Q4 22	$14M
Q1 23	$14M
Q2 23	$16M
Q3 23	$13M
Q4 23	$25M
Q1 24	$15M
Q2 24	$30M
Q3 24	$30M
Q4 24	$40M
Q1 25	$29M
Q2 25	$20M
Q3 25	$15M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 21	+4.3%	+3.4%
Q1 22	+4.6%	+0.3%
Q2 22	+2.0%	-0.1%
Q3 22	-0.4%	-3.1%
Q4 22	-1.8%	-4.9%
Q1 23	+1.1%	+4.2%
Q2 23	-4.2%	+9.1%
Q3 23	-0.7%	+11.1%
Q4 23	-0.2%	+9.3%
Q1 24	-3.1%	+5.9%
Q2 24	+9.7%	+14.2%
Q3 24	-0.4%	+9.3%
Q4 24	+11.5%	+12.8%
Q1 25	+3.7%	+9.1%
Q2 25	-0.6%	+120.4%
Q3 25	+5.6%	-7.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 21	$6M	1.6%
Q1 22	$6M	1.7%
Q2 22	$0	0.0%
Q3 22	$9M	2.3%
Q4 22	$6M	1.4%
Q1 23	$4M	1.0%
Q2 23	$5M	1.4%
Q3 23	$5M	1.4%
Q4 23	$6M	1.5%
Q1 24	$6M	1.5%
Q2 24	$7M	1.7%
Q3 24	$4M	1.2%
Q4 24	$7M	1.6%
Q1 25	$2M	0.5%
Q2 25	$5M	1.3%
Q3 25	$6M	1.4%

OpEx Breakdown

Quarter	R&D	SG&A
Q4 21	$25M	$162M
Q1 22	$24M	$160M
Q2 22	$26M	$161M
Q3 22	$25M	$144M
Q4 22	$27M	$152M
Q1 23	$27M	$167M
Q2 23	$27M	$165M
Q3 23	$27M	$162M
Q4 23	$24M	$163M
Q1 24	$27M	$166M
Q2 24	$30M	$195M
Q3 24	$27M	$177M
Q4 24	$31M	$179M
Q1 25	$25M	$181M
Q2 25	$27M	$180M
Q3 25	$22M	$169M

Revenue Segments

Quarter	Codman Specialty Surgical	Tissue Technologies
Q4 21	$271M	$135M
Q1 22	$247M	$129M
Q2 22	$258M	$140M
Q3 22	$250M	$135M
Q4 22	$265M	$133M
Q1 23	$248M	$133M
Q2 23	$271M	$110M
Q3 23	$268M	$114M
Q1 24	$256M	$112M
Q2 24	$302M	$116M
Q3 24	$271M	$110M
Q4 24	$315M	$128M
Q1 25	$281M	$102M
Q2 25	$304M	$112M
Q3 25	$293M	$109M

Revenue by Geography

Quarter	Asia Pacific	Europe	Rest Of World	United States	Rest Of The World
Q4 21	$45M	$51M	$22M	$288M	—
Q1 22	$48M	$44M	$22M	$263M	—
Q2 22	$43M	$47M	$20M	$287M	—
Q3 22	$43M	$38M	$22M	$282M	—
Q4 22	$43M	$42M	$19M	$294M	—
Q1 23	$50M	$41M	$18M	$271M	—
Q2 23	$48M	$37M	$19M	$277M	—
Q3 23	$49M	$42M	$22M	$270M	—
Q1 24	$50M	$42M	$22M	$256M	—
Q2 24	$46M	$41M	$21M	$310M	—
Q3 24	$37M	$34M	$19M	$290M	—
Q4 24	$44M	$42M	—	$336M	—
Q1 25	$45M	$35M	—	$282M	$20M
Q2 25	$48M	$43M	—	$306M	$19M
Q3 25	$43M	$43M	—	$296M	$21M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$407M	$0	$407M
Q2 22	$447M	$0	$447M
Q3 22	$512M	$0	$512M
Q4 22	$457M	$0	$457M
Q1 23	$307M	$0	$307M
Q2 23	$309M	$0	$309M
Q3 23	$274M	$0	$274M
Q4 23	$276M	$33M	$309M
Q1 24	$592M	$71M	$663M
Q2 24	$215M	$82M	$297M
Q3 24	$215M	$62M	$278M
Q4 24	$246M	$27M	$274M
Q1 25	$239M	$34M	$273M
Q2 25	$218M	$36M	$254M
Q3 25	$232M	$36M	$268M
Q4 25	$235M	$29M	$264M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 21	86M	+0.4%	+1.0%
Q1 22	84M	-1.8%	-1.2%
Q2 22	84M	-0.8%	-2.0%
Q3 22	83M	-0.3%	-2.4%
Q4 22	84M	+0.3%	-2.5%
Q1 23	82M	-1.6%	-2.3%
Q2 23	81M	-1.4%	-3.0%
Q3 23	80M	-1.7%	-4.3%
Q4 23	78M	-1.9%	-6.4%
Q1 24	78M	-0.8%	-5.6%
Q2 24	77M	-0.4%	-4.6%
Q3 24	76M	-1.2%	-4.2%
Q4 24	77M	+0.7%	-1.7%
Q1 25	76M	-0.7%	-1.6%
Q2 25	76M	0.0%	-1.2%
Q3 25	77M	+0.4%	+0.4%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 21	$106.7K	4K
Q1 22	$99.1K	4K
Q2 22	$104.7K	4K
Q3 22	$101.4K	4K
Q4 22	$106.9K	4K
Q1 23	$102.3K	4K
Q2 23	$102.4K	4K
Q3 23	$102.7K	4K
Q4 23	$100.6K	4K
Q1 24	$93.5K	4K
Q2 24	$106.0K	4K
Q3 24	$96.5K	4K
Q4 24	$100.7K	4K
Q1 25	$87.0K	4K
Q2 25	$94.5K	4K
Q3 25	$91.5K	4K

Revenue / Employee